

September 30, 2024

**EN Otsuka Pharmaceutical Co., Ltd. obtains marketing approval of  
“ENOSOLID<sup>®</sup> Semi Solid for Enteral Use”**

EN Otsuka Pharmaceutical Co., Ltd. (Head Office: Hanamaki, Iwate, Japan; President and Representative Director: Satoshi Muneyuki; hereinafter, “EN Otsuka Pharmaceutical”) has obtained the marketing approval of “ENOSOLID<sup>®</sup> Semi Solid for Enteral Use” on September 24, 2024.

This product is a semi-solid enteric nutrition formula which appropriately contains major nutrients, vitamins and trace elements based on the typical Japanese nutrition intake pattern (as of 2020). It is directed at nutrition management of patients who require less maintenance energy. Nutrition administration of 900 kcal supplies roughly the recommended or targeted volume of vitamins and trace elements to be taken per day. This product contains L-carnitine\*<sup>1</sup> involved in fatty acid metabolism and inulin\*<sup>2</sup> as dietary fiber.


Solid diet is generally thought to take longer time than liquid diet to move from the stomach and be less likely to cause reflux to the esophagus, which increases and accelerates administration of semi-solid nutrition via gastric fistula in recent years. In this situation, we have launched RACOL-NF<sup>®</sup> Semi Solid for Enteral Use (hereinafter, “RACOL Semi Solid”), the first semi-solid enteral nutrition formula as a prescription drug in 2014. With 1,600 kcal nutrition, this product was designed to provide patients with close to the recommended or targeted volume of vitamins and trace elements required per day. Recently, there have been demands in the clinical environment for another product of nutrition management for patients who require less management energy.

EN Otsuka Pharmaceutical and Otsuka Pharmaceutical Factory, Inc., responsible for information supply, continue to provide information and products useful for appropriate nutrition management, aiming to be the best partner for patients and healthcare professionals in the field of clinical nutrition. Based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide," the Otsuka Group is dedicated to contributing to the health of people around the world.

\*1 L-carnitine: A micronutrient which plays an important role in production of energy from fat.

\*2 Water-soluble dietary fiber contained abundantly in onion, burdock root, etc. and widely used as sweetener and food additive

Product Information

Brand name	ENOSOLID <sup>®</sup> SemiSolid for Enteral Use
Regulatory classification	None
Storage	Store at room temperature
Date of approval	September 24, 2024
Indications	Generally used to maintain nutrition of postoperative patients, and particularly for enteral feeding of patients who find it difficult to eat and drink orally for a long period of time
Dosage and administration	<p>The usual adult dosage is in the reference range of 900 -1,500 g (900-1,500 kcal) /day via gastric fistula into the stomach in several feedings. The administration speed should be 2-4 minutes per 100 g (6-12 minutes per 300 g). The maximum dosage per feeding should be 600 g.</p> <p>Patients should be observed carefully and checked for clinical symptoms after initial feeding. The daily dosage should be increased over several days up to the reference range.</p> <p>Dosage and administration speed should be appropriately increased/decreased depending on the age, weight, symptoms, and nutritional condition.</p>
Packaging	 <p>18 bags (300 g/bag × 18)</p>

## Company Profile

### EN Otsuka Pharmaceutical Co., Ltd.

Established	:	March 26, 2002
Capital	:	1.51 billion yen
Representative	:	Satoshi Muneyuki, President, and Representative Director
Head Office	:	4-3-5 Nimaibashi, Hanamaki, Iwate Prefecture 025-0312, Japan
Employees	:	372 (as of December 31, 2023)
Business Description	:	Research & development, manufacturing, sales, and the export/import of enteral nutrients, foods for medical use, foods for the elderly, disease-specific foods
URL	:	<a href="https://www.enotsuka.co.jp/en/">https://www.enotsuka.co.jp/en/</a>

### Otsuka Pharmaceutical Factory, Inc.

Established	:	October 7, 1969 (founded September 1, 1921)
Capital	:	80 million yen
Representative	:	Shuichi Takagi, President, and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,318 (as of December 31, 2023)
Business Description	:	Manufacture, sale, import and export of pharmaceuticals, medical devices, and functional foods with a focus on clinical nutritional products.
URL	:	<a href="https://www.otsukakj.jp/en/">https://www.otsukakj.jp/en/</a>